Skip over generic navigation
Skip over primary navigation
Skip over visual
Skip over functional column
July 4, 2012
Following the initial announcement in 2011, the basic planning for the construction of a 20,000 mt plant for the production of the specialty plastic polyamide 12 (PA12) in Asia is now entering the final phase. Subject to the approval of the relevant bodies, the new plant will be built in Singapore and is scheduled to be completed by 2014. Adding to the capacity of the existing facility in Europe, this second production plant for PA12 in Singapore is designed to substantially increase the availability of the product and its guaranteed delivery. It will also bring Evonik even closer to its customers in Asia’s fast-growing markets. Ever since the fire at a plant that manufactures CDT, a precursor of PA12, in Marl Chemical Park at the end of March 2012, Evonik has continued to press ahead with its plans to build the PA12 plant in Singapore. Gregor Hetzke, head of Performance Polymers Business Unit of Evonik, confirms: "Our goal in significantly expanding our capacity is to consolidate our leading position for polyamide 12 in the long term." PA12 is used in innovative, high-quality products in the automotive sector, electrics and electronics, household equipment, sports equipment as well as in manufacturing industry. Together with some of its customers, Evonik has also developed new PA12-based applications for oil and gas production as well as for the solar industry. Evonik markets PA12 as a construction material under the VESTAMID® brand name and as a coating powder under the name VESTOSINT®. The damaged CDT plant in Marl is currently being repaired and, according to current planning, is expected to recommence operations in the fourth quarter of 2012. Afterwards, Evonik’s entire PA12 capacity will be available once more.
Evonik, the creative industrial group from Germany, is one of the world leaders in specialty chemicals. Profitable growth and a sustained increase in the value of the company form the heart of Evonik’s corporate strategy. Its activities focus on the key megatrends health, nutrition, resource efficiency, and globalization. Evonik benefits specifically from its innovative prowess and integrated technology platforms. Evonik is active in over 100 countries around the world. In fiscal 2011 more than 33,000 employees generated sales of around €14.5 billion and an operating profit (adjusted EBITDA) of about €2.8 billion.
In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.